In Japan, a research center network consisting of Kyoto University to provide clinical-grade
induced Pluripotent Stem Cells (iPSC) and several major research centers to develop iPSC …

Induced pluripotent stem cells (iPSCs) are derived from somatic cells through a
reprogramming process, which converts them to a pluripotent state, akin to that of embryonic …

Human embryonic stem cells (hESCs) represent a potential source of blood cells for
transfusion therapies and a promising tool for studying the ontogeny of hematopoiesis …

Introduction The induced pluripotent stem cell (iPSC) technology allows generation of
patient-specific pluripotent stem cells, thereby providing a novel cell-therapy platform for …

Generation of induced pluripotent stem cells (iPSCs) has revolutionized the field of
regenerative medicine by providing researchers with a unique tool to derive disease-specific …

Mesenchymal stem cells (MSCs) represent the most clinically used stem cells in
regenerative medicine. However, due to the disadvantages with primary MSCs, such as …

Human pluripotent stem cells are known to have the capacity to renew indefinitely, being
intrinsically able to differentiate into many different cell types. These characteristics have …

The last 5 years have witnessed a significant increase in the number of clinical studies
based on human pluripotent stem cells (hPSCs). In parallel, concern is increasing about the …

Human ESC and iPSC are an attractive source of cells of high quantity and purity to be used
to elucidate early human development processes, for drug discovery, and in clinical cell …

The promise of off-the-shelf cellular therapeutics (CTPs) based on allogeneic induced
pluripotent stem cells (iPSCs) may be hindered by alloimmunity, leading many to suggest …